Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could help endoscopists catch stomach cancer earlier

NCT ID NCT07551466

Diagnosis Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing an artificial intelligence (AI) model designed to help doctors detect early gastric (stomach) cancer during endoscopy. The AI combines images from standard and enhanced endoscopy with patient data to improve accuracy and explain its reasoning. Researchers will enroll 100 adults with suspicious stomach lesions to see how well the AI performs compared to standard diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this AI tool could help endoscopists detect early gastric cancer more reliably, potentially leading to earlier treatment and better outcomes.
What could go wrong
This is an observational study with only 100 participants, so the AI model may not perform as well in larger, more diverse groups. It is not yet ready for widespread clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with suspected gastric lesions who underwent endoscopic examination and endoscopic submucosal dissection (ESD), with available white-light imaging (WLI), magnifying endoscopy with narrow-band imaging (ME-NBI), and histopathological diagnosis at participating centers.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Suspicious gastric lesions identified on white-light imaging (WLI) * Preoperative biopsy indicating precancerous lesions (dysplasia or intraepithelial neoplasia) or adenocarcinoma, with preoperative magnifying endoscopy with narrow-band imaging (ME-NBI) performed * Patients meeting the absolute indications for endoscopic submucosal dissection (ESD) and who underwent ESD Exclusion Criteria: * Non-adenocarcinoma histological types (e.g., lymphoma) * Patients who did not undergo ME-NBI examination or did not receive ESD * Lesions invading the muscularis propria or deeper layers * Missing or indeterminate postoperative histopathological results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early gastric cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric neoplasm microinvasive gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.